InvestorsHub Logo
Followers 80
Posts 24703
Boards Moderated 1
Alias Born 09/08/2000

Re: None

Friday, 02/17/2017 9:26:19 AM

Friday, February 17, 2017 9:26:19 AM

Post# of 27622
IMNP - .1825 Pre-market now at .21/.217

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia



Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.